Literature DB >> 30706395

Current Use of Adenovirus Vectors and Their Production Methods.

Ekramy E Sayedahmed1, Rashmi Kumari1, Suresh K Mittal2.   

Abstract

Various adenovirus (AdV) vector systems have proven to be lucrative options for gene delivery. They can serve as potential vaccine candidates for prevention of several common infectious diseases and hold the promise for gene therapy, especially for cancer. Several AdV vector-based therapies are currently at various stages of clinical trials worldwide, which make an immense interest of both the clinicians and researchers. Since these vectors are easy to manipulate, have broad tropism, and have the capability to yield high titers, this delivery system has a wide range of applications for different clinical settings. This chapter emphasizes on some of the current usages of AdV vectors and their production methods.

Entities:  

Keywords:  Adenovirus vector; Gene delivery system; Gene therapy; Recombinant vaccines; Vector design; Vector production

Mesh:

Year:  2019        PMID: 30706395      PMCID: PMC8761255          DOI: 10.1007/978-1-4939-9065-8_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  75 in total

1.  Adenoviruses: group name proposed for new respiratory-tract viruses.

Authors:  J F ENDERS; J A BELL; J H DINGLE; T FRANCIS; M R HILLEMAN; R J HUEBNER; A M PAYNE
Journal:  Science       Date:  1956-07-20       Impact factor: 47.728

Review 2.  Gutless adenovirus: last-generation adenovirus for gene therapy.

Authors:  R Alba; A Bosch; M Chillon
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

3.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

Authors:  Sai V Vemula; Omar Amen; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Virus Res       Date:  2013-09-17       Impact factor: 3.303

Review 8.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

9.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

10.  Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

Authors:  Geraldine A O'Hara; Christopher J A Duncan; Katie J Ewer; Katharine A Collins; Sean C Elias; Fenella D Halstead; Anna L Goodman; Nick J Edwards; Arturo Reyes-Sandoval; Prudence Bird; Rosalind Rowland; Susanne H Sheehy; Ian D Poulton; Claire Hutchings; Stephen Todryk; Laura Andrews; Antonella Folgori; Eleanor Berrie; Sarah Moyle; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Loredana Siani; Alison M Lawrie; Sarah C Gilbert; Adrian V S Hill
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

View more
  4 in total

Review 1.  Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.

Authors:  Schwartze Jt; Havenga M; Bakker Wam; Bradshaw Ac; Nicklin Sa
Journal:  J Mol Med (Berl)       Date:  2022-05-24       Impact factor: 5.606

2.  Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.

Authors:  Ignazio Caruana; Francesca Del Bufalo; Claudia Manuela Arnone; Vinicia Assunta Polito; Angela Mastronuzzi; Andrea Carai; Francesca Camassei Diomedi; Laura Antonucci; Lucia Lisa Petrilli; Maria Vinci; Francesco Ferrari; Elisa Salviato; Marco Scarsella; Cristiano De Stefanis; Gerrit Weber; Concetta Quintarelli; Biagio De Angelis; Malcolm K Brenner; Stephen Gottschalk; Valentina Hoyos; Franco Locatelli
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

3.  A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice.

Authors:  Arshad Khan; Ekramy E Sayedahmed; Vipul K Singh; Abhishek Mishra; Stephanie Dorta-Estremera; Sita Nookala; David H Canaday; Min Chen; Jin Wang; K Jagannadha Sastry; Suresh K Mittal; Chinnaswamy Jagannath
Journal:  Cell Rep Med       Date:  2021-08-17

Review 4.  Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.

Authors:  Ahmed Elkashif; Marwa Alhashimi; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Clin Transl Immunology       Date:  2021-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.